Microfluidic Peptide/mRNA Complexes Enable Robust Pulmonary Delivery

Study Background and Research Question

The therapeutic potential of RNA molecules—especially messenger RNA (mRNA) and small interfering RNA (siRNA)—has surged in recent years, driven by the ability of these molecules to modulate gene expression for a range of diseases. Pulmonary delivery of RNA offers direct access to the respiratory tract, which is especially relevant for treating lung diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and respiratory viral infections. However, a major barrier for clinical translation is the lack of safe and efficient delivery systems that can withstand the physical and biochemical stresses encountered during inhalation-based administration.

Historically, lipid nanoparticles (LNPs) have dominated non-viral RNA delivery, yet they are susceptible to destabilisation under aerosolisation and in the phospholipid-rich environment of airway lining fluids. This leads to a loss in structural integrity and reduced transfection efficiency, especially after processes such as spray drying or nebulisation. Addressing these challenges, the study by Ma et al. (2025) investigates whether synthetic cationic peptides, formulated with RNA via microfluidic mixing, can serve as robust alternatives for inhalable RNA delivery.

Key Innovation from the Reference Study

The central innovation in this work is the use of microfluidic mixing to reproducibly and controllably assemble complexes of synthetic cationic peptides (LAH4-L1 and PEG12KL4) with either siRNA or mRNA. This approach produces peptide/RNA nanoparticles that retain their ability to deliver RNA effectively, even after being subjected to the stresses of nebulisation. Importantly, the study demonstrates that both the particle size and transfection efficiency of these complexes remain stable post-nebulisation—a critical requirement for inhaled therapeutics targeting the lung.

This marks a significant advancement over conventional LNP-based systems, which can suffer destabilisation and reduced efficacy after aerosolisation, as highlighted in the reference paper. The microfluidic method also facilitates precise control over particle characteristics and batch reproducibility, which are essential for clinical translation.

Methods and Experimental Design Insights

The research team employed two cationic peptides (LAH4-L1 and PEG12KL4) as non-viral vectors for complexing with siRNA and mRNA. Four formulations were prepared: LAH4-L1/siRNA, PEG12KL4/siRNA, LAH4-L1/mRNA, and PEG12KL4/mRNA. Microfluidic mixing was chosen for its ability to yield homogenous nanoparticles with consistent characteristics. The protocol was optimised to ensure maximal RNA binding and minimal aggregation.

After formulation, the peptide/RNA complexes were subjected to aerosolisation using a vibrating mesh nebuliser, which generates a fine inhalable mist. The aerodynamic properties of the resulting aerosol were characterised, focusing on the mass median aerodynamic diameter (MMAD), which must be <5 μm for efficient pulmonary deposition. The hydrodynamic diameter of the complexes was measured before and after nebulisation, and the binding efficiency of RNA within the complexes was quantified. Finally, the transfection efficiency was evaluated in two lung-derived cell lines (A549 and BEAS-2B), both pre- and post-nebulisation, to determine whether the delivery vehicles retained functionality.

Protocol Parameters

• Peptide/RNA complex preparation: Use microfluidic mixing under optimised flow rates to ensure homogenous nanoparticle formation and RNA encapsulation.
• Nebulisation: Employ a vibrating mesh nebuliser to generate aerosol droplets with MMAD <5 μm for effective lung deposition.
• Particle characterisation: Assess hydrodynamic diameter and polydispersity index before and after nebulisation; target post-nebulisation sizes around 100 nm for optimal uptake.
• Transfection assessment: Quantify gene expression in A549 and BEAS-2B cells, comparing performance pre- and post-nebulisation to evaluate system stability and efficacy (see study).

Core Findings and Why They Matter

The study found that all peptide/RNA formulations could be effectively aerosolised, producing inhalable mists with MMAD values below 5 μm—suitable for deep lung deposition. Remarkably, the process of nebulisation reduced the hydrodynamic diameter of the complexes to approximately 100 nm, irrespective of their original size. Despite this size reduction, the RNA binding efficiency and in vitro transfection capability were preserved, with no statistically significant differences observed between pre- and post-nebulisation samples.

These findings demonstrate that peptide-based vectors, when formulated via microfluidic mixing, can endure the mechanical and interfacial stresses of aerosol generation. This is particularly relevant for the development of pulmonary RNA therapeutics, as it addresses the major hurdle of maintaining delivery system functionality after inhalation-based administration. The work suggests a viable path toward non-viral, inhalable RNA drugs for a range of respiratory diseases.

Comparison with Existing Internal Articles

Several internal resources discuss the challenges and solutions for mRNA delivery and analysis in mammalian systems, with a particular focus on fluorescently labeled and chemically modified mRNA. For instance, the article "ARCA Cy5 EGFP mRNA (5-moUTP): Elevating Fluorescent mRNA..." highlights the utility of 5-methoxyuridine modified, Cy5-labeled mRNA for precise delivery and localization studies. These modified mRNAs are engineered to enhance translational efficiency and suppress innate immune activation, features that complement the peptide-based delivery systems developed in the reference study.

Another resource, "ARCA Cy5 EGFP mRNA (5-moUTP): Enabling Quantitative mRNA...", underscores the role of such fluorescently labeled mRNA in robust, quantitative assays of delivery efficiency and intracellular trafficking. In both cases, the focus is on tools that allow researchers to measure and optimize mRNA delivery, paralleling the endpoint assays used in the peptide/mRNA nebulisation study.

In summary, while the internal articles primarily address analytical and workflow tools for tracking mRNA in vitro, the reference study provides a new, robust platform for delivering functional RNA to the lung in vivo, with both domains benefiting from advances in mRNA modification and labeling strategies.

Limitations and Transferability

Despite its promising findings, the study does have limitations. The experiments were conducted in vitro using lung-derived cell lines, which may not fully recapitulate the complex biological barriers present in the human lung. While transfection efficiency was maintained after nebulisation, the long-term stability of the peptide/RNA complexes in airway fluids and their immunogenicity in vivo remain to be established. Additionally, the scalability and manufacturability of microfluidic mixing at industrial scales require further investigation.

Transferability to other RNA types, peptide vectors, or disease models will depend on further validation. Nonetheless, the method provides a flexible and generalizable framework for testing new delivery vectors or modified mRNA constructs, especially those designed for pulmonary administration.

Why this cross-domain matters, maturity, and limitations

The transition from in vitro delivery and localization assays—such as those enabled by fluorescently labeled, 5-methoxyuridine modified mRNA—to robust, in vivo pulmonary delivery systems is critical for translating RNA therapeutics to the clinic. The maturity of peptide-based vectors for inhalable RNA delivery is still evolving, but the preservation of activity after nebulisation is a significant milestone. However, translation to clinical application will require further in vivo studies, assessment of delivery efficiency and immune response in animal models, and eventual human trials.

Research Support Resources

For researchers seeking to benchmark or validate their own mRNA delivery systems, tools such as ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009) provide a practical resource. This 5-methoxyuridine modified, fluorescently labeled mRNA enables direct visualization and quantification of mRNA uptake, localization, and translation efficiency in mammalian cells, supporting workflows similar to those described in the reference study. When integrated with modern delivery vectors and analytical platforms, these resources help accelerate the design and evaluation of next-generation mRNA delivery systems.